GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2009

Quantum Immunologics to Commercialize Auburn University’s Veterinary Cancer Immunotherapy

  • Quantum Immunologics (QI) entered into an agreement with Auburn University to bring its cancer immunotherapy to the veterinary market. An independently funded and jointly owned company will be formed to accomplish this goal.

    QI will provide corporate and administrative management of the new company as well as license its oncofetal antigen-based therapy to serve as the collaboration's underlying technology. The partnership will draw upon Auburn's companion animal oncology expertise along with its animal clinical trial experience.

    "This collaboration provides a best-of-both-worlds approach,” according to QI's CEO Chuck Broes. “We have a tremendous respect for Auburn's renowned veterinary institution and believe that this collaboration provides a natural synergy, allowing both parties to maximize one another's core competencies. We also believe that this initiative will allow QI to capitalize upon the significant veterinary market." QI anticipates that the new company will begin operations in mid-2010.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »